Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2012.11.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2014English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Invasive Mucinous Carcinoma of the Breast

Baylor University Medical Center Proceedings
Medicine
2013English

PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?

Breast Cancer Research
Cancer ResearchOncology
2014English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Identification of Aberrant Gene Expression During Breast Ductal Carcinoma in Situ Progression to Invasive Ductal Carcinoma

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma in Situ to Invasive Carcinoma of the Breast

Modern Pathology
Forensic MedicinePathology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy